The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.
A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.
For a start-up looking to build a patent portfolio, where should you start—‘home-grown’ patents, or licensing others’ IP?
Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.
Monster Energy has failed to block a UK trademark filed by German pharmaceutical company Merck KGaA.
The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
The COVID-19 pandemic has seen the fundamental principles of the IP system called into question. How can we go on as before?
The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
IP firm Rouse will collaborate with life sciences service provider Codex to support companies looking to enter the Chinese market.
In a victory for Mylan, the English High Court has rejected Israel-based pharmaceutical company Neurim’s attempt to delay a generic version of its insomnia medication.